Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PAVmed
MedTech
PAVmed staves off Nasdaq delisting as net loss widens
After its allotted six months to regain compliance with the Nasdaq’s listing rules passed by without success, PAVmed has bought a bit of extra time.
Andrea Park
Jun 29, 2023 1:29pm
PAVmed and its Lucid, Veris subsidiaries lay off 20% of staff
Jan 18, 2023 11:11am
Lucid Diagnostics files for $58M IPO to leave the PAVmed nest
Sep 23, 2021 11:54am
Lucid's DNA test for esophageal cancer lands EU approval
Jun 14, 2021 8:40am
PAVmed’s new digital health spinout banks first acquisition
Jun 2, 2021 3:10pm
